With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for
patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very …

Thrombotic microangiopathy is a rare but serious complication that affects kidney transplant
recipients. It appears in 0.8–14% of transplanted patients and negatively affects graft and …

The objective of this guideline is to provide healthcare professionals with clear, up‐to‐date
and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) …

Results Acute phase atypical hemolytic uremic syndrome–activated plasma induced an
increased C5b-9 deposition on endothelial cells. Standard and lower doses of eculizumab …

Thrombotic microangiopathy (TMA) is defined by specific clinical characteristics, including
microangiopathic hemolytic anemia, thrombocytopenia, and pathologic evidence of …

Thrombotic microangiopathy (TMA) is one of the most devastating sequalae of kidney
transplantation. A number of published articles have covered either de novo or recurrent …

Introduction Posttransplant thrombotic microangiopathy (PT-TMA) is an uncommon event
that characterizes approximately 3% to 14% of kidney transplants (KTs), and that is …

Thrombotic microangiopathy (TMA) is a rare and devastating complication of kidney
transplantation, which often leads to graft failure. Posttransplant TMA (PT-TMA) may occur …

Thrombotic microangiopathy (TMA) is characterized by microangiopathic hemolytic anemia,
thrombocytopenia and organ injury occurring due to endothelial cell damage and …

Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenia purpura (TTP) are rare
diseases sharing a common pathological feature, thrombotic microangiopathy (TMA). TMA is …